HealthQuartzabout 1 hour ago
FDA Advisers Vote on Grail Blood Test
3 min read
FDA advisers vote Wednesday on Grail Inc.'s Galleri blood test as Medicare coverage hangs in the balance. The test detects up to 50 cancer types and costs $949 out of pocket. Trials enrolled over 140,000 participants in the U.K. and 35,000 in North America, though the primary endpoint failed. The FDA considers harms from inaccurate results before deciding.
Level
Hype check
Tap to vote and see what everyone thinks.